ADaptiVe Biomarker Trial That InformS Evolution of Therapy
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs BMS 986156 (Primary) ; BMS 986205 (Primary) ; Cabiralizumab (Primary) ; Ipilimumab (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms ADVISE
- Sponsors Bristol-Myers Squibb
- 13 Feb 2018 Planned End Date changed from 14 Mar 2021 to 31 Jan 2022.
- 13 Feb 2018 Planned primary completion date changed from 14 Mar 2021 to 30 Jan 2020.
- 13 Feb 2018 Status changed from not yet recruiting to recruiting.